Canopy Growth (TSX:WEED; NYSE: CGC) acquired This Works in an all-cash transaction for £43 million. British-based This Works offers a range of high-quality natural skincare and sleep solution products, including deep...
Investment banker Brookline Capital Markets entered into a partnership with broker-dealer, Arcadia Securities. The transaction allows Brookline to capitalize on and expand its growing presence in the public capital...
BeyondSpring’s (NASDAQ:BYSI) abstract on its lead asset, Plinabulin, has been accepted for poster presentation at the International Society for Pharmacoeconomics and Outcomes Research 2019 conference May 18-22 in New...
The Chinese patent office granted Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) a notice of acceptance for its light activated photodynamic compounds (PDC) intended to safely and effectively destroy various cancers...
The FDA has accepted Abeona Therapeutics (NASDAQ:ABEO) IND application for AB-202 for the treatment of CLN1 disease. CLN1 disease, also known as infantile Batten disease, is caused by a mutation in the PPT1 gene. In...
Oragenics (NYSE American:OGEN) has enrolled more than 80 patients in its Phase 2 trial of AG013 for the treatment of oral mucositis (OM). The company also reported that the WHO provided AG013 with the generic name...
Biocept (NASDAQ:BIOC) launched its multi-gene liquid biopsy panel for the detection of biomarkers associated with lung cancer. The difficulty of obtaining lung tissue samples from patients has previously limited access...
Compugen (NASDAQ:CGEN) dosed the first patient in its Phase 1 trial of COM701, in combination with Opdivo, in patients with advanced solid tumors. The Phase 1 study will assess the safety and tolerability of COM701, a...
Principia Biopharma (NASDAQ:PRNB) reported that PRN1371 was well tolerated in the dose escalation portion of its Phase 1 trial in adult patients with advanced solid tumors. PRN1371, a fibroblast growth factor receptor...